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Abstract: BODIPY dyes have recently attracted attention as potential photosensitizers. In this work,
commercial and novel photosensitizers (PSs) based on BODIPY chromophores (haloBODIPYs and
orthogonal dimers strategically designed with intense bands in the blue, green or red region of the
visible spectra and high singlet oxygen production) were covalently linked to mesoporous silica
nanoparticles (MSNs) further functionalized with PEG and folic acid (FA). MSNs approximately
50 nm in size with different functional groups were synthesized to allow multiple alternatives of
PS-PEG-FA decoration of their external surface. Different combinations varying the type of PS
(commercial Rose Bengal, Thionine and Chlorine e6 or custom-made BODIPY-based), the linkage
design, and the length of PEG are detailed. All the nanosystems were physicochemically character-
ized (morphology, diameter, size distribution and PS loaded amount) and photophysically studied
(absorption capacity, fluorescence efficiency, and singlet oxygen production) in suspension. For the
most promising PS-PEG-FA silica nanoplatforms, the biocompatibility in dark conditions and the
phototoxicity under suitable irradiation wavelengths (blue, green, or red) at regulated light doses
(10–15 J/cm2) were compared with PSs free in solution in HeLa cells in vitro.
Keywords: BODIPY-based photosensitizers; functionalized silica nanoparticles; folic acid; PEG;
photodynamic therapy; HeLa cells; (photo) toxicity
1. Introduction
Currently, several alternatives are used to treat cancer, including surgery and chemo,
radio- or immune-therapy, although depending on the type of cancer an effective method
has not been found yet. In this regard, Photodynamic Therapy (PDT) is a complementary
treatment that can be applied as a combined therapy to enhance anticancer efficiency by
a synergic or additive effect with conventional methods. PDT involves a light source, a
photosensitizer (PS), and oxygen. During PDT, PS is activated under light at a specific
wavelength to generate reactive oxygen species (ROS), mainly singlet oxygen (1O2), a
cytotoxic species able to promote apoptosis or necrosis of cancer cells [1]. Nowadays,
preclinical and clinical trials have proven PDT to be effective in early-stage tumors or
the palliation of advanced cancers, such as skin, head, neck, esophageal, or lung cancer,
improving patient survival [2–5]. PDT is considered a less invasive and more precise
treatment (locally controlled by the light irradiation of malignant tissue), without inducing
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long-term side effects, and it has a lower cost with respect to other treatments. Nevertheless,
the limitations of PDT are mainly related to the availability of the PSs. Despite there being
several PSs approved by the FDA, most of them are hydrophobic and/or tend to have poor
selectivity to malignant tissues [6–9].
The ideal PS to be used as a photoactive drug for PDT should be non-cytotoxic in dark
conditions, selective to cancer tissues, and display limited stability in vivo to minimize
side effects; it should have intense absorption bands (ε ≥ 50,000 M−1 cm−1), preferentially
in the phototherapeutic window to ensure deeper penetration of light into tissues [10]
(630–850 nm), and high singlet oxygen production to reduce doses and irradiation time; it
should be photoresistant to avoid the photodecomposition of the PS during treatment; and
finally, it should present an amphiphilic nature, being soluble in water as well as permeable
through the cell membrane. At the moment, few PSs fulfill these requirements, and new
molecular designs are required [6,7,11–14]. One approach for obtaining new molecules is
focused on the synthesis of improved PS to overcome their limitations, but this usually
requires multistep chemistry, increasing the costs and production time, hampering the
implementation for clinical uses. In this context, BODIPY dyes have recently attracted atten-
tion as potential photosensitizers [15–18]. They are characterized by intense absorption and
emission bands in the green region, and resistance to photobleaching [19,20]. Despite being
highly fluorescent chromophores (antagonistic property to ROS generation) and poorly
soluble in water, their synthesis allows easy, versatile, and selective modification of their
molecular structure to increase the population of the triplet state, and consequently their
singlet oxygen generation, while also shifting their spectroscopic bands into the clinical
window. These modifications include the addition of iodine heavy atoms, π-conjugated sys-
tems in the BODIPY skeleton, or the design of orthogonal BODIPY dimers [15,17,18,21–33].
Further functionalization of the BODIPY chromophore is related with the incorporations of
different targets to increase their solubility in aqueous media and enhance their selectivity
to cancer cells [14,34–39].
Another alternative is the use of nanomaterials as (photo)drug carriers. They have
a large surface-to-volume ratio, which allows the administration of a large amount of
active components, preventing their degradation or inactivation by plasma components,
delivering soluble and stable formulations in aqueous media, and enhancing their accumu-
lation inside tumor tissues by so-called passive targeting due to the enhanced permeability
and retention (EPR) effect [11,40–49]. Additionally, the selectivity to cancer cells can be
improved by active targeting through surface modifications with target ligands, such as
proteins, polysaccharides, nucleic acids, peptides and small molecules that bind to specific
receptors overexpressed on the surface of malignant cells but not on healthy cells [9,50–52].
Currently, there are many different types of nanoparticles based on liposomes, poly-
meric, micellar, metallic, or protein for medical use [40–46,53–55]. In this regard, silica
nanoparticles (SN) have attracted attention as carriers for drug delivery due to their proper-
ties, which include reduced toxicity, good biocompatibility, high surface area, easy function-
alization, optical transparency, and low cost [56,57]. PS-loaded silica nanoparticles have
been reported as promising singlet oxygen generator platforms, improving the photoactive
drug delivery by enhancing PS poor solubility and selectivity for cancer cells [58–62]. The
PS can be physically encapsulated or covalently attached to the internal or external surface
of the silica nanoparticles [63–67]. Briefly, loading PS within the nanostructure ensures a
high photostability but restrains the diffusion of oxygen species (molecular oxygen towards
inside and singlet oxygen towards outside). It has been demonstrated that nanoparticles
with draped-PS outside lead to better 1O2 productivity than PS located inside [68–70].
In the last few years, diverse nanoplatform designs have been used as vehicles to
carry BODIPY-PS [71–81], or even BODIPY-based nanoparticles, through the self-assembly
process [79,80,82–88]. However, despite the advantageous properties of SN, mentioned
above, few examples can be found in the literature of their use as carriers for BODIPY-
PSs [89,90].
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In this work, different PSs (Figure 1) were tethered to the external surface of 50 nm
MSNs. First, three commercially available PSs, Rose Bengal (RB), Chlorin e6 (C6), and
Thionine (Th), recognized as suitable singlet oxygen generators and extensively employed
in PDT, were used [6,9–11,59,91–93]. These dyes already have functional groups in their
molecular structure (carboxylic in Rose Bengal and Chlorin e6 and amine in Thionine)
and can be easily grafted to the external surface of MSNs. Afterward, seven custom-made
BODIPY-based PSs were used, which were rationally designed to effectively generate
high singlet oxygen production under illumination at different wavelengths of the visible
spectra (blue, green or red light) [12,18,24,31,94,95], and to endow suitable graftable groups
to be anchored at MSNs.
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Figure 1. Molecular st ucture of the different c mpounds anchored to MSN: commercial (RB, Th, C6)
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groups (Si-PEG and NHS-PEG) and molecular weight (750 Da, 2000 Da and 5000 Da), and FA.
Additionally, MSNs were externally coated with polyethylene glycol (PEG), as it is
usually required to stabilize nanoparticle systems, enhance their life-time in the blood
system and avoid the induction of immune responses [44,47,49,94–98]. For that, several
PEG derivatives (Figure 1) with different graftable groups at one end of the chain (succin-
imide group or with silyl group Si-PEG) were tethered at the MSN shell. The length of the
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polymer chain (750 Da, 2000 Da, and 5000 Da) was also adjusted to improve nanoparticle
stabilization in water.
Finally, the selectivity of MSNs for cancer cells was enhanced by the addition of a
peripheral target for cancer cells. Folic acid (FA), a low-cost, stable and small molecule with
available functional groups (Figure 1), is widely used to target several types of cancer cells,
in particular, those overexpressing folate receptors (FR) on their surface, such as ovarian,
endometrial and kidney cancer cells [99,100]. Thus, tethering FA on the nanoparticle’s
surface promotes a higher cellular uptake via endocytosis [101–104]. In fact, our recently
published study quantitatively demonstrated a significantly higher accumulation of FA-
functionalized fluorescent MSNs compared to nanoparticles without FA in HeLa cells [105].
The linkage between the PSs and the MSNs and the length of PEG were firstly opti-
mized with the commercial PS Rose Bengal and then implemented for the rest of PSs. The
physicochemical features (morphology, diameter, size distribution, PS loaded amount) and
photophysical properties (absorption capacity, fluorescence efficiency, and singlet oxygen
production) were detailed. The efficiency of the PS-PEG-FA MSN nanoplatforms was tested
in HeLa cells in vitro, and the results were compared with those obtained in cells exposed
to PSs free in solution.
2. Results and Discussion
2.1. Silica Nanoparticles Characterization
Mesoporous silica nanoparticles with a suitable size for medical applications and
particularly for PDT [98,106] were synthesized by the modified Stöber method [107] as
described elsewhere [105]. The external surface of mesoporous nanoparticles surface was
functionalized with amino group (NH-MSN) or carboxylic group (COOH-MSN). The
latter type was obtained after conversion of CN-MSN in acidic conditions, according to
the synthesis route described in Materials and methods section and Supporting Material.
Bare MSNs analyzed by SEM and TEM showed spherical morphology and mesoporous
structure (Figure 2 and Figure S1), with a size distribution of 50 ± 10 nm. The external
functionalization of MSNs was studied by XPS (Table S1). The presence of 5% of nitrogen
atoms in both NH-MSN and CN-MSN confirmed the existence of amine/cyano functional
groups located outside of the nanoparticles whereas the absence of nitrogen atoms in
the COOH-MSN indicates an effective conversion of CN into COOH groups. In the case
of FTIR spectra (Figure S2), an intense peak located at υ = 1110–1000 cm−1 as well as
a wide band placed at υ = 3650–3200 cm−1 were recorded in every sample spectrum,
and are assigned to Si-O-C and O-H groups, respectively. A characteristic band of cyane
group (C≡N) at υ = 2260–2240 cm−1 was recorded in CN-MSN, which disappeared in the
COOH-MSN system (Figure S2 blue), indicating again the total conversion from -CN to
-COOH. Furthermore, the typical band of COOH group (COO-H υ = 3550–2550 cm−1, C=O
υ = 1775–1650 cm−1) was also registered in COOH-MSN.
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The sizes of the three types of nanosystems were also characterized in water suspen-
sion by DLS. Both NH-MSN and COOH-MSN showed similar hydrodynamic diameter,
of around 60–70 nm, to the size of the nanoparticles by TEM (Table 1), whereas the larger
diameter, derived for CN-MSN, of 280 nm, indicates a tendency to form aggregates. Zeta
potential values obtained for CN-MSN but also for NH-MSN (≤±25 mv) [108] confirm
a poorer stability in water with respect to COOH-MSN system. The higher stability of
this later functionalized COOH-MSN is attributed to the presence of carboxylic groups at
the external surface, partially deprotonated (COO−) in aqueous media and the superficial
negative charge makes the nanosystem more stable by electrostatic repulsion, Table 1.
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Actually, the MSNs’ stability in aqueous media is certainly controlled by the type
and the number of molecules lodged at the external surface. It has been demonstrated
that the presence of organic PSs makes the external surface of MNS more hydrophobic,
promoting nanoparticles agglomeration, hindering their stability in aqueous media [109].
Note here that the particle–particle aggregation is detrimental to singlet oxygen production
and should be avoided or minimized. To optimize the PS loading and to ensure the
stability of the nanoparticles in suspension, several syntheses were carried out for the
amine-functionalized MSN (NH-MSN), employing commercial RB as PS and different PEG
derivatives (RB-PEGn-NH-MSN). The combinations were focused on the variation of (i)
the functional group of the MSN (OH-, or NH2-) at which PS and PEG molecules were
attached, and (ii) the length of PEG chain (750 Da, 2000 Da, and 5000 Da).
2.2. Optimization of the Functionalization of Silica Nanoparticles with Rose Bengal as PS
Rose Bengal is a commercial PS with an intense absorption band (λmax = 556 nm;
ε = 9.8·104 M−1cm−1) and high singlet oxygen production (Φ∆ = 0.86 in CH3OD). The
carboxylic function in the RB molecular structure allows the covalent grafting to be inserted
to amine groups or to the intrinsic hydroxyl groups of the external surface of MSN [109].
Nevertheless, both RB-MSN nanosystems (RB grafted at the external NH2 or OH) showed
instantaneous flocculation in water media and the suspension was only viable in less polar
solvents. Since stable nanoparticle suspension in water is crucial to obtain competitive
hybrid nanocarriers for PDT [109], pegylation of the outside of MSNs is required to avoid
the precipitation of the nanoparticles. Firstly, to optimize the stabilization of the system,
NHS-PEG of different chain length (750 Da, 2000 Da and 5000 Da) were linked to the amine
groups of the silica, while RB was anchored in OH groups (samples RB-PEG750-NP-a,
RB-PEG2000-NP-a, and RB-PEG5000-NP-a in Table 2).
According to zeta potential (Table 2), the least favored value (−4.3 mV) was registered
for sample RB-PEG750-NP-a with the shortest PEG chain in this series, indicating its
inefficiency at improving the stability of RB-MSN in water. Indeed, a similar value of
around -4 mV was obtained for NH-MSN without RB (Table 1). In contrast, PEG of
higher molecular weight, 2000 Da and 5000 Da (RB-PEG2000-NP-a and RB-PEG5000-NP-a in
Table 2) rendered Zpot values of −25 mV, indicating good stability of these nanosystems in
water. The longer PEG-5000 did not lead to an improvement of the stability with respect
to PEG-2000, which could likely be assigned to a different conformation adopted at the
external surface [110]. Additionally, long PEG chains can also impede the internalization
of nanoparticles into the cells [111,112]. Thus, a PEG of 2000 Da was selected as the most
suitable, and was employed in the rest of the samples.
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Table 2. RB amount, nanoparticle size and their Zeta potential by DLS in water of the different
RB-PEG-MSNs.


















5000 114 −25.0 20
RB-PEG-NP-b RB-NH2-MSNPEG-OH-MSN 2000 95 −29.0 10
RB-PEG-NP-c RB-OH-MSNPEG-OH-MSN 2000 88 −31.0 20
Next, different anchorages between PEG and MSN (at a fixed PEG length of 2000 Da)
were also tested. The anchoring of Si-PEG (silylated PEG of 2000 Da, Figure 1) to the
external OH-groups of MSN, samples RB-NP-b and RB-NP-c, led to even higher Zpot
values with respect to sample RB-PEG2000-NP-a (with PEG at the amine groups), Table 2.
This fact is possibly due to a higher presence of PEG at the surface because there are more
accessible OH-groups than NH2-groups at the silica external surface [97]. This assumption
was confirmed for RB, showing a double dye loading when was tethered to OH with
respect to NH2 groups of the MSN external surface (RB-PEG-NP-b vs. RB-PEG-NP-c in
Table 2) [109].
The stability of the nanoparticles can also be studied by the absorption spectra of
the RB-PEG-MSNs samples in water suspension (Figure 3). The registered bands for RB-
PEG2000-a and RB-PEG5000-a, practically identical, showed more prominent shoulders at
both sides of the main absorption band, indicative of a higher dye aggregation tendency.
Indeed, according to the absorption spectra, the dye aggregation follows the tendency
RB-PEG5000-NP-a ≈ RB-PEG2000-NP-a > RB-PEG-NP-c > RB-PEG-NP-b. For the samples
RB-PEG2000-NP-a, RB-PEG5000-NP-a, and RB-PEG-NP-c (RB grafted at the hydroxyl groups
of MSNs, Table 2) the estimated RB loading was equal, and consequently, the observed dye
aggregation in these samples should be assigned to interparticle processes, as supported by
Zpot values and previously attributed to a lower presence of PEG molecules at the external
surface. Sample RB-PEG-NP-b, with RB loading at the amine groups half of that obtained
for the RB at the hydroxyl groups (sample RB-PEG-NP-b vs. sample RB-PEG-NP-a in
Table 2), showed a narrower absorption band, not much different from that recorded for
RB in diluted solution [105]. However, reducing the cargo of PS per nanoparticle would
compel a higher concentration of nanoparticles per volume to reach effective PS doses for
PDT in the cells, which would also promote particle-particle agglomeration. For this reason,
the optimization of the samples is not a trivial task, and the quantification of their singlet
oxygen production would be a good indicator of their applicability in cells. Significantly,
all the samples, except for RB-PEG750-NP-a, showed a similar singlet oxygen quantum
yield, with values around Φ∆ ≈ 0.80–0.85 in deuterated methanol (CH3OD), similar to that
registered for RB in the same solvent (Φ∆ = 0.86). The fact that RB grafted to MSN can
generate singlet oxygen as efficiently as the RB in solution is indicative of the potential use
of these nanosystems in PDT [65,67,108].
In this context, we considered MSNs with PS and PEG at OH- groups the best nanosys-
tems for PDT in terms of maximized PS loading with good stability in aqueous media. Nev-
ertheless, in the series of novel in lab-made BODIPY-based PS, homologous molecular struc-
ture with carboxyl or silylated groups as graftable groups are proposed (BDP2 vs. BDP3;
BDP4 vs. BDP5 and BDP6 vs. BDP7 in Figure 1) to compare their respective PDT action for
a normalized concentration of PS incubated in cells. In a further step, FA was anchored
through its carboxylic function to the amine groups of NH-MSN to increase the nanosystem
internalization into cells, as demonstrated in a former work [105]. The presence of FA
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at the external surface of PS-PEG-MSNs also assists to the stability of the nanoparticles
reducing the interparticle aggregation as it was experimentally verified by the absorption
spectra of RB in sample RB-PEG-NP-d (Figure 3) in comparison with sample RB-PEG-NP-c
without FA, and whose band shape resembles that of RB in the sample of RB-PEG-NP-b.
The successful tethering of FA at the MSNs was checked by its characteristic band at 350 nm
(Figure S3) [105,113], although its accurate quantification was not possible because of the
important scatter contribution in this region.
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Figure 5. Confocal fluorescence microscopy images (λex = 561 nm and λem = 565–615 nm) of HeLa cells exposed to RB free
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2.3. Photosensitized Silica Nanoparticles with Other Photosensitizers
Concerning the in-lab synthesized PSs, the molecular design of the novel lab-made
BODIPY-PSs was based on previous studies [18,23,114–116]. The best choice to promote
the intersystem crossing in haloBODIPY is the iodination at the 2 and 6 positions of the
BODIPY core (BDP2 and BDP3), reaching singlet oxygen production ≥80% under green
illumination (Table S2). Another alternative without using halide atoms to preclude the
cytotoxic effect inherent to heavy atoms [26,28,117–119], is based on orthogonal BODIPY
dimers [120] (BDP4 and BDP5). Generally, these dyads are endowed with very intense
absorption bands in the green region, as well as high singlet oxygen generation (Φ∆ > 75%,
Table S2) promoted by intra-charge transfer states [121–123]. To shift the absorption
band to the blue region (BDP1), a nitrogen atom was placed at the meso position of the
BODIPY together with iodines at 2 and 6. The formation of a hemicyanine-like structure
induced a very pronounced blue-shift, placing the main absorption band in the blue
region (at around 420–440 nm) [22] but keeping a good singlet oxygen generation (≈80%,
Table S2). Most interestingly for PDT, to shift the absorption into the clinic window
(650–850 nm), conjugated systems [116], particularly styryl groups with electron-donating
methoxy groups in 3 and 4 positions of the phenyl ring, were added at the 3 and 5 positions,
accompanied by iodine atoms at the 2 and 6 positions (BDP6 and BDP7). The singlet
oxygen quantum yield achieved for these red-haloBODIPYs was lower, at around 45%
(Table S2) with respect to the other BDP-PS in this series, but they revealed an emission
Int. J. Mol. Sci. 2021, 22, 6618 9 of 23
ability of around 20%, which can enable fluorescence imaging, in contrast to the rest of
the non-emissive haloBDP (Φfl ≤ 0.03, Table S2). Additionally, graftable groups were also
incorporated in the meso position into all of these BODIPYs to allow their linking to MSNs.
Thus, PSs (commercial and lab-made) were classified according to their absorption
range (blue, green and red) and their respective graftable groups (silylated: BDP1, BDP3,
BDP5 and BDP7; carboxylic: C6, BDP2, BDP4 and BDP6; and amine group: Th, Figure 1).
The outer surface of MSNs was also decorated with PEG and FA, tethering at the hydroxyl
groups of MSN and at amine groups, respectively, except for the COOH-MSN, in which
a modified folic acid, FA-HDA (see Materials and Methods section), was linked to the
carboxylic groups.
The photophysical features, the singlet oxygen production and the phototoxic action
of PS-PEG-FA-MSNs in HeLa cells were compared with their chemically homologous PSs
with carboxylic group since the silylated ones polymerize in cell culture media (Figure 6,
Table 3 and Table S2).
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Figure 6. Normalized absorption spectra of PS in CHCl3 solution (brown) and the PS tethered at 
the external surface of MSN together with PEG and FA (black) in CH3OH at 0.5 mg/mL. The 
absorption spectra for all the PS-MSN samples were recorded after stirring the nanosystems for at 
least 24 h. 
Figure 6. Normalized absorption spectra of PS in l3 solution (bro n) a t t the
ext rnal surface of MSN togeth r with PEG and FA (black) in CH3O at 0.5 mg/ L. The absorption
spectra for all the PS-MSN samples were recorded after stirring the nanosystems for at least 24 h.
2.4. In Vitro Experiments in HeLa Cells
The most representative lab-made PS-MSNs were tested in HeLa cells, applying differ-
ent light sources depending on the absorption band positions: BDP1-NP (λmax = 435 nm)
under blue irradiation (λmax = 435 nm at 10 J/cm2), BDP3-NP, BDP4-NP and BDP5-NP
(λmax = 510–530 nm) under green irradiation (λmax = 518 nm at 10 J/cm2) and finally
C6-NP and BDP6-NP (λmax = 635–660 nm) were irradiated under red light (λmax = 655 nm
at 15 J/cm2). Unfortunately, none of our available irradiation sources (blue, green or red,
see experimental section) were suitable to activate the Th photosensitizer (λab ≈ 600 nm).
Under dark conditions, some PSs free in solution, such as halo-BODIPY, BDP2 and
BDP6, as well as the commercial C6, were toxic to HeLa cells at concentrations ≥1 µM
(Figures 7 and 8, Table S3). On the other hand, when these PSs were grafted to the MSNs no
cytotoxicity was observed under dark conditions (Figure 7, Figure 8, Figure S4). In general
terms, PS-PEG-FA-MSN did not show any toxicity under dark conditions (Table S4), except
for the BDP4-NP (Figure S5) sample with a low PS loading at the MSN (5 µmol/g, Table 3),
which required a higher amount of nanoparticles (≈0.9 mg/mL) to achieve an equal PS
concentration of 5 µM incubated in HeLa cells. To avoid cytotoxicity and to guarantee
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the safe use of PS-PEG-FA-MSN, the upper limit was set at 1 mg/mL, a value in good
agreement with a former work [105].
Table 3. Cargo of PS at MSNs, absorption maxima (λab) and the singlet oxygen quantum yield in

















































The BDP1-NP nanosystem was able to induce around 70% cell death at 1 µM of PS
concentration and near 90% cell death at 5 µm under blue light irradiation, leading to a
EC50 = 1.0 µM (Figure S4). Better performance was revealed by the haloBDP nanosystem
BDP3-NP activated by green irradiation light, which induced ≥80% cytotoxicity under
light exposure at 0.5 µM PS and ≥90% at 1 µM PS (Figure 7A), providing an EC50 of 0.4 µM
(Table S4) without any cytotoxic effects under dark conditions. However, although the
homologous haloBDP BDP2 free in solution induced higher phototoxicity under light
conditions (Figure 7B, Table S3), attributed to a higher oxygen singlet production than
PS at the MSN surface (Φ∆ = 0.95 vs. 0.70, Table 3 and Table S2, respectively), it also
induced cytotoxicity under dark conditions (EC50(DARK) ≈ 4 mM, Table S3). Conversely,
halogen-free BODIPY dimer BDP4 did not show toxicity in the dark, but its phototoxicity
action was also greatly reduced (Figure 7C). However, the fact that this heavy-atom-free PS
did not show dark toxicity allows a safe increase of the dimer incubated doses, reaching a
75% and 90% decrease of cell viability at 5 µM and 10 µM PS concentrations, respectively
(Figure 7C).
Please note that the phototoxicity is drastically enhanced when the BODIPY dimer
is loaded at the MSN surface (e.g., BDP5-NP) leading to an EC50 value 40 times higher
(Tables S3 and S4). The Figure 6C,D show how BDP5-NP induced a decrease of 90–100%
in HeLa viability at 0.5 µM, whereas nearly no phototoxicity was observed for the BODIPY
dimer at the same concentration. The lower cytotoxicity effect under light irradiation
of BDP4, a larger molecule with a lesser solubility in aqueous solution, could be likely
assigned to a poor internalization into the cells.
Int. J. Mol. Sci. 2021, 22, 6618 11 of 23
Int. J. Mol. Sci. 2021, 22, x FOR PEER REVIEW 11 of 24 
 
 
µM (Table S4) without any cytotoxic effects under dark conditions. However, although 
the homologous haloBDP BDP2 free in solution induced higher phototoxicity under light 
conditions (Figure 7B, Table S3), attributed to a higher oxygen singlet production than PS 
at the MSN surface (ΦΔ = 0.95 vs. 0.70, Tables 3 and S2, respectively), it also induced 
cytotoxicity under dark conditions (EC50(DARK) ≈ 4 mM, Table S3). Conversely, halogen-
free BODIPY dimer BDP4 did not show toxicity in the dark, but its phototoxicity action 
was also greatly reduced (Figure 7C). However, the fact that this heavy-atom-free PS did 
not show dark toxicity allows a safe increase of the dimer incubated doses, reaching a 75% 
and 90% decrease of cell viability at 5 µM and 10 µM PS concentrations, respectively 
(Figure 7C). 
Please note that the phototoxicity is drastically enhanced when the BODIPY dimer is 
loaded at the MSN surface (e.g., BDP5-NP) leading to an EC50 value 40 times higher (Ta-
bles S3 and S4). The Figures 6C,D show how BDP5-NP induced a decrease of 90–100% in 
HeLa viability at 0.5 µM, whereas nearly no phototoxicity was observed for the BODIPY 
dimer at the same concentration. The lower cytotoxicity effect under light irradiation of 
BDP4, a larger molecule with a lesser solubility in aqueous solution, could be likely as-
signed to a poor internalization into the cells. 
 
Figure 7. Cell viability (MTT assay) of HeLa cells exposed to the PSs in solution BDP2 (A) and 
BDP4 (C) and to their corresponding nanosystems BDP3-NP (B) and BDP5-NP (D) under 
dark conditions (blue bars) and after green irradiation at 10 J/cm2 (orange bars). Stars indicate 
significant differences with respect to controls. Asterisks indicate significant differences be-
tween dark and light conditions at the same concentrations tested. 
These promising results demonstrated the efficiency of functionalized MSNs to suc-
cessfully transport PSs into HeLa cells, promoting higher phototoxicity at a lower concen-
tration of PSs in comparison with the PS free in solution, and avoiding cytotoxicity under 
dark conditions. Most importantly, the proposed BDP-PEG-FA-MSNs (both iodinated 
and orthogonal BODIPY dimers) showed a higher phototoxicity effect in comparison to 
analogous nanosystems loaded with commercial RB under the same green light doses 
(Figures 4 and 7, and Table S4). 
The designed BDP-based PSs for red-irradiation generally displayed lower 
phototoxicity with respect to those in the green region (Figure 8 vs. Figure 7), which is in 
agreement with their lower oxygen singlet production (Tables 3 and S2). However, the 
































BDP4 concentration (x 10-7 M)
dark
light
* * * **






























BDP5-NP concentration (x 10-7 M)
dark
light
* * * **
* * * **
Figure 7. Cell viability (MTT assay) of HeLa cells exposed to the PSs in solution BDP2 (A) and BDP4 (C) and to their
corresponding nanosystems BDP3-NP (B) and BDP5-NP (D) under dark conditions (blue bars) and after green irradiation
at 10 J/cm2 (orange bars). Stars indicate significant differences with respect to controls. Asterisks indicate significant
differences between dark and light conditions at the same concentrations tested.
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Figure 8. Cell viability (MTT assay) of HeLa cells exposed to PSs in soluti n C6 (A) and BDP6 (C) and to their respective the
nanosystems C6-NP (B), and BDP6-NP (D) under dark conditions (blue bars) and after red irra iation at 15 J/cm2 (orange
bars). Stars indicate significant differences with respec to controls. Asterisks indicate significant differences between dark
and l ght conditions at the same concentrations sted.
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These promising results demonstrated the efficiency of functionalized MSNs to suc-
cessfully transport PSs into HeLa cells, promoting higher phototoxicity at a lower concen-
tration of PSs in comparison with the PS free in solution, and avoiding cytotoxicity under
dark conditions. Most importantly, the proposed BDP-PEG-FA-MSNs (both iodinated
and orthogonal BODIPY dimers) showed a higher phototoxicity effect in comparison to
analogous nanosystems loaded with commercial RB under the same green light doses
(Figures 4 and 7, and Table S4).
The designed BDP-based PSs for red-irradiation generally displayed lower phototoxi-
city with respect to those in the green region (Figure 8 vs. Figure 7), which is in agreement
with their lower oxygen singlet production (Table 3 and Table S2). However, the red-
BODPY-PS demonstrated a higher ability to kill cells under red light irradiation than the
commercial and widely used C6, despite a lower oxygen singlet production with respect
to C6. The lower oxygen singlet production is balanced with a higher absorption coeffi-
cient, reaching higher phototoxicity (Table S2) and resulting in lower EC50 under red light
irradiation (Table S3), but also higher cytotoxicity under dark conditions (Figure 8A–C).
Although the photoactivity of the red-PSs loaded at MSN, samples BDP6-NP and
C6-NP, with respect to PSs free in solution was inferior, once again, MSNs hampered the
inherent toxicity of PSs in dark, which is of interest for clinical studies. In this context, PDT
efficiency could be increased by safely applying higher concentrations of PS-MSNs and by
increasing the exposure time of the irradiation [124]. Additionally, these functionalized
nanosystems loaded with red-BDP PS were endowed with enough brightness to be tracked
by fluorescence microscopy (Figure S6).
3. Materials and Methods
3.1. Materials and Methods
All starting materials and reagents for the MSNs synthesis were used as commer-
cially provided unless otherwise indicated. Tetraethoxysilane (TEOS) (≥99%), ammonium
hydroxide solution (NH4OH) (25% NH3 basis), hexadecyltrimethylammonium bromide
(CTAB) (≥98%), 3-aminopropyltrimethoxysilane (APTMS) (97%), 3-cyanopropyltriethoxysilane
(CTES) (98%), 3-aminopropyltriethoxysilane (APTES) (99%), 1-hydroxybenzotriazole hy-
drate (HOBt) (≥97%), boron trifluoride diethyl etherate (for synthesis), dimethylformamide
anhydrous (DMF) (99.8%), 3,4-dimethoxybenzaldehyde (99%), piperidine (≥99.5%), 2,3-
dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) (98%), N-hydroxysuccimide (NHS) (98%),
N-(3-(dimethylaminopropyl)-N’-ethylcarbodiimide (EDC) (≥97%), triethylamine (TEA)
(≥99%) and folic acid (FA) (≥97%) were purchased from Sigma-Aldrich (St. Louis, MO,
USA); Ethyl chloroformate (≥99%) and 2,4-dimethylpyrrole (97%) were supplied by Acros
(Geel, Belgium); trifluoroacetic acid (TFA) (99%) was purchased from Alfa Aesar (Haver-
hill, MA, USA); acetic acid glacial (synthesis grade) from Scharlab (Debrecen, Hungary);
polyethylene glycol (Si-PEG) (2000 Da, >95%) from Iris BIOTECH GMBH (Maktredwitz,
Germany); NHS-PEG derivative (750 Da (>95%) and 2000 Da (>95%), supplied by Iris
BIOTECH GMBH, and 5000 Da (≥80%) by Sigma-Aldrich.
3.2. Synthesis of New BODIPY-Based PSs
3.2.1. General
Anhydrous solvents were prepared by distillation over standard drying agents ac-
cording to common methods. All other solvents were of HPLC grade and were used as
provided. Flash chromatography was performed using silica gel (230–400 mesh). NMR
spectra were recorded using CDCl3 or CDCl3/CD3OD at 20 ◦C. 1H NMR and 13C NMR
chemical shifts (δ) were referenced to internal solvent CDCl3 (δ = 7.260 and 77.03 ppm,
respectively) or CD3OD (δ = 3.205/4.031 and 52.69 ppm, respectively). Multiplicity is
indicated as follows: s = singlet; d = doublet; dd = double doublet; t = triplet; q = quadru-
plet; quint = quintuplet; m = multiplet. Coupling constants (J) are dated in hertz (Hz).
DEPT 135 experiments were used to determine the type of carbon nucleus (C vs. CH vs.
CH2 vs. CH3). FTIR spectra were obtained from neat samples using the attenuated total
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reflection (ATR) technique. High-resolution mass spectrometry (HRMS) was performed
using electronic impact (EI) or MALDI-TOF and ion trap (positive mode) for the detection.
BDP1 [109], BDP2 [125], 8-(4-carboxyphenyl)-2-formyl-1,3,5,7-tetramethylBODIPY [126]
and 8-(4-carboxyphenyl)-2,6-diiodo-1,3,5,7-tetramethylBODIPY [127] were synthesized by
the corresponding described methods. The synthesis of BODIPYs BDP3-BDP7 is illustrated
in Scheme S1 (see Supplementary Materials).
3.2.2. General Procedure for the Formation of Amides
The corresponding carboxy-BODIPY (1 mol. equiv.), APTES (2.1 mol. Equiv.), TEA
(2 mol. equiv.), EDC (2 mol. equiv.) and HOBt (2 mol. equiv.) were dissolved in CH2Cl2
and stirred under argon at rt for 12 h. The reaction mixture was then washed with HCl
10% and water. The obtained organic layer was dried over anhydrous Na2SO4, filtered and
the solvent evaporated to dryness. The obtained residue was submitted to purification by
flash chromatography on silica gel.
3.2.3. Synthesis of BDP3
According to the general procedure described in Section 3.2.2., BDP2 [125] (70 mg,
0.12 mmol), APTES (0.06 mL, 0.25 mmol), TEA (0.03 mL, 0.24 mmol), EDC (46 mg,
0.24 mmol) and HOBt (32 mg, 0.24 mmol) in CH2Cl2 (10 mL) were reacted. Flash chro-
matography (CH2Cl2/EtOAc, 90:10) afforded BDP3 (39 mg, 41%) as an orange-red solid.
1H NMR (300 MHz, CDCl3) δ 5.84 (t, J = 5.4 Hz, 1H, NH), 3.82 (q, J = 6.9 Hz, 6H, 3CH2O),
3.26 (q, J = 6.9 Hz, 2H, CH2N), 3.11–3.05 (m, 2H, CH2), 2.61 (s, 6H, 2CH3), 2.49 (s, 6H,
2CH3), 2.32 (t, J = 6.9 Hz, 2H, CH2), 1.99–1.90 (m, 2H, CH2), 1.64 (quint, J = 7.8 Hz, 2H,
CH2), 1.22 (t, J = 6.9 Hz, 9H, 3CH3), 0.64 (t, J = 7.8 Hz, 2H, CH2Si) ppm. 13C NMR (75 MHz,
CDCl3) δ 171.1 (CONH), 155.5 (C), 145.3 (C), 142.5 (C), 131.5 (C), 86.6 (C-I), 58.5 (CH2), 41.9
(CH2), 36.1 (CH2), 28.4 (CH2), 27.3 (CH2), 22.9 (CH2), 19.0 (CH3), 18.3 (CH3), 16.2 (CH3),
7.9 (CH2) ppm. FTIR ν 3302, 2971, 2924, 1712, 1620, 1542, 1463, 1392, 1346, 1190, 1084, 1003,
958 cm−1. HRMS-EI m/z 789.0931 (calcd. for C26H40BF2I2N3O4Si: 789.0939).
3.2.4. Synthesis of BDP4
To a degassed solution of 8-(4-carboxyphenyl)-2-formyl-1,3,5,7-tetramethylBODIPY [126]
(186 mg, 0.47 mmol) in dry CH2Cl2 (15 mL) were added a solution of 2,4-dimethylpyrrole
(0.10 mL, 0.98 mmol) in dry CH2Cl2 (2 mL) and two drops of TFA, and the resulting mixture
stirred at rt for 2 h. After, a solution of DDQ (117.0 mg, 0.51 mmol) in CH2Cl2 (10 mL) was
added, and the resulting new mixture stirred for 30 min. Then, TEA (0.32 mL, 2.34 mmol)
and BF3 Et2O (0.58 mL, 4.68 mmol) were added to the mixture, and the resulting final
mixture stirred for 3 h at rt, washed with HCl 10%, and water. The obtained organic layer
was dried over anhydrous Na2SO4, filtered and the solvent evaporated to dryness. Flash
chromatography (CH2Cl2/EtOAc, 30:70) afforded BDP4 (78 mg, 27%) as an orange solid.
1H NMR (300 MHz, CDCl3) δ 8.27 (d, J = 8.1 Hz, 2H, 2CH), 7.46 (d, J = 8.1 Hz, 2H, 2CH),
6.10 (s, 1H, CH), 5.99 (s, 2H, 2CH), 2.61 (s, 3H, CH3), 2.52 (s, 6H, 2CH3), 2.42 (s, 3H, CH3),
1.71 (s, 6H, 2CH3), 1.41 (s, 3H, CH3), 1.21 (s, 3H, CH3) ppm. 13C NMR (75 MHz, CDCl3)
δ 170.6 (COOH), 159.4 (C), 155.9 (C), 151.3 (C), 145.2 (C), 142.3 (C), 140.7 (C), 140.2 (C),
138.0 (C), 133.2 (C), 132.0 (C), 131.8 (C), 131.2 (CH), 130.4 (C), 130.3 (C), 128.4 (CH), 126.0
(C), 122.9 (CH), 121.3 (CH), 14.9 (CH3), 14.8 (CH3), 14.6 (CH3), 14.0 (CH3), 12.8 (CH3), 12.3
(CH3) ppm. FTIR ν 2924, 2855, 1709, 1546, 1464, 1311, 1193, 1078, 981 cm−1. HRMS-EI m/z
614.2636 (calcd. for C33H32B2F4N4O2: 614.2648).
3.2.5. Synthesis of BDP5
According to the general procedure described in Section 3.2.2, BDP4 (46 mg, 0.07 mmol),
APTES (0.04 mL, 0.15 mmol), TEA (0.02 mL, 0.14 mmol), EDC (28 mg, 0.14 mmol) and
HOBt (20 mg, 0.15 mmol) in CH2Cl2 (10 mL) were reacted. Flash chromatography (hex-
ane/EtOAc, 60:40) afforded BDP5 (30 mg, 49%) as an orange solid. 1H NMR (300 MHz,
CDCl3) δ 7.95 (d, J = 8.1 Hz, 2H, 2CH), 7.39 (d, J = 8.1 Hz, 2H, 2CH), 6.71 (t, J = 5.4 Hz,
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1H, NH), 6.08 (s, 1H, CH), 5.98 (s, 2H, 2CH), 3.82 (q, J = 6.9 Hz, 6H, 3CH2O), 3.50 (q,
J = 6.0 Hz, 2H, CH2N), 2.60 (s, 3H, CH3), 2.52 (s, 6H, 2CH3), 2.41 (s, 3H, CH3), 1.79 (quint,
J = 7.8 Hz, 2H, CH2), 1.70 (s, 6H, 2CH3), 1.39 (s, 3H, CH3), 1.21 (t, J = 6.9 Hz, 9H, 3CH3),
1.20 (s, 3H, CH3), 0.73 (t, J = 7.8 Hz, 2H, CH2Si) ppm. 13C NMR (75 MHz, CDCl3) δ 166.3
(CONH), 159.2 (C), 155.8 (C), 151.1 (C), 145.3 (C), 142.3 (C), 141.1 (C), 138.1 (C), 137.6
(C), 135.8 (C), 133.3 (C), 132.2 (C), 131.8 (C), 130.5 (C), 128.2 (CH), 128.1 (CH), 125.9 (C),
122.8 (CH), 121.3 (CH), 58.6 (CH2O), 42.4 (CH2), 22.8 (CH2), 18.3 (CH3), 14.83 (CH3), 14.80
(CH3), 14.6 (CH3), 13.9 (CH3), 12.8 (CH3), 12.3 (CH3), 8.0 (CH2) ppm. FTIR ν 2924, 2854,
1646, 1546, 1513, 1310, 1193, 1078, 980 cm−1. HRMS-MALDI-TOF m/z 817.3979 (calcd. for
C42H53B2F4N5O4Si: 817.3989).
3.2.6. Synthesis of BDP6
8-(4-Carboxyphenyl)-2,6-diiodo-1,3,5,7-tetramethylBODIPY [127] (25 mg, 0.04 mmol)
in DMF (2 mL), 3,4-dimethoxybenzaldehyde (20 mg, 0.12 mmol), piperidine (0.02 mL,
0.20 mmol) and acetic acid (0.01 mL, 0.20 mmol) were added to a microwave tube. The
tube was sealed with an aluminum cap and heated for 20 min at 80 ◦C under microwave
radiation (Biotage® Initiator Classic, Uppsala, Sweden). After being cooled down to rt,
CH2Cl2 was added and the organic layer washed with water, dried over anhydrous Na2SO4,
filtered, and evaporated to dryness. The obtained residue was submitted to purification
by flash chromatography on silica gel with EtOAc/CH3OH (95:5) to give BDP6 (16 mg,
43%) as a green solid. 1H NMR (700 MHz, CDCl3/CD3OD 4:1) δ 8.09 (d, J = 8.4 Hz, 2H,
2CH), 7.98 (d, J = 16.8 Hz, 2H, 2CH=C), 7.42 (d, J = 16.8 Hz, 2H, 2C=CH), 7.30 (d, J = 8.4 Hz,
2H, 2CH), 7.09 (dd, J = 8.4 and 2.1 Hz, 2H, 2CH), 7.04 (d, J = 2.1 Hz, 2H, 2CH), 6.78 (d,
J = 8.4 Hz, 2H, 2CH), 3.82 (s, 6H, 2CH3O), 3.79 (s, 6H, 2CH3O), 1.31 (s, 6H, 2CH3) ppm. 13C
NMR (176 MHz, CDCl3/CD3OD 4:1) δ 172.0 (COOH), 154.7 (C), 154.4 (C), 153.1 (C), 149.5
(C), 143.7 (C), 143.6 (CH), 143.5 (CH), 141.1 (C), 136.4 (C), 135.9 (C), 134.8 (CH), 134.7 (CH),
133.8 (C), 132.7 (CH), 132.6 (CH), 125.8 (CH), 120.7 (CH), 115.2 (CH), 115.1 (CH), 113.7
(CH), 87.1 (C-I), 59.82 (CH3O), 59.78 (CH3O), 21.5 (CH3) ppm. FTIR ν 2924, 2852, 1694,
1591, 1514, 1461, 1265, 1176, 1101, 1012 cm−1. HRMS-MALDI-TOF m/z 906.0638 (calcd. for
C37H35BF2I2N2O6: 906.0646).
3.2.7. Synthesis of BDP7
According to the general procedure described in Section 3.2.2, BDP6 (37 mg, 0.04 mmol),
APTES (0.02 mL, 0.085 mmol), TEA (0.01 mL, 0.08 mmol), EDC (15 mg, 0.08 mmol) and
HOBt (11 mg, 0.08 mmol) in CH2Cl2 (10 mL) were reacted for 12 h. Flash chromatography
(CH2Cl2/EtOAc, 90:10) afforded BDP7 (14 mg, 32%) as a red solid. 1H NMR (700 MHz,
CDCl3) δ 8.12 (d, J = 16.8 Hz, 2H, 2CH=C), 7.99 (d, J = 8.4 Hz, 2H, 2CH), 7.57 (d, J = 16.8 Hz,
2H, 2C=CH), 7.41 (d, J = 8.4 Hz, 2H, 2CH), 7.23 (dd, J = 8.4 and 1.4 Hz, 2H, 2CH), 7.16 (d,
J = 1.4 Hz, 2H, 2CH), 6.90 (d, J = 8.4 Hz, 2H, 2CH), 6.79 (t, J = 6.3 Hz, 1H, NH), 3.96 (s,
6H, 2CH3O), 3.93 (s, 6H, 2CH3O), 3.86 (q, J = 7.0 Hz, 6H, 3CH2O), 3.54 (q, J = 6.3 Hz, 2H,
CH2N), 1.85–1.80 (m, 2H, CH2), 1.43 (s, 6H, 2CH3), 1.24 (t, J = 7.0 Hz, 9H, 3CH3), 0.77 (t,
J = 7.7 Hz, 2H, CH2Si) ppm. 13C NMR (176 MHz, CDCl3) δ 166.4 (CONH), 150.7 (C), 150.5
(C), 149.2 (C), 145.4 (C), 139.6 (CH), 138.4 (C), 137.0 (C), 135.9 (C), 132.6 (C), 129.8 (C), 128.8
(CH), 128.1 (CH), 121.9 (CH), 116.9 (CH), 111.1 (CH), 109.7 (CH), 83.3 (C-I), 58.6 (CH2O),
56.1 (CH3O), 56.0 (CH3O), 42.4 (CH2), 22.8 (CH2), 18.4 (CH3), 17.8 (CH3), 8.0 (CH2) ppm.
FTIR ν 3487, 2921, 2852, 1743, 1514, 1463, 1176, 1099, 1014 cm−1. HRMS-MALDI-TOF m/z
1119.1824 (calcd. for C47H54BF2I2N3O8Si: 1119.1831).
3.3. Synthesis of the MSNs
The synthesis of mesoporous silica nanoparticles with amine groups at the exter-
nal surface (NH-MSNs) has been described previously [105,109]. The synthesis route of
mesoporous silica nanoparticles with carboxylic group (COOH-MSN) is similar to that
described for NH-MSN, but in the second step, CTES (0.007 mmol) is added instead of
APTMS to provide cyane groups at the external surface. After collection, CN-MSNs were
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re-suspended in acid solution (H2O:H2SO4 50:50 v/v) and stirred under 140 ◦C for 12 h
to convert the CN into COOH groups. Then, the sample was cooled down to rt and kept
under stirring for another 24 h. Finally, the COOH-MSNs were washed several times with
water, until neutral supernatants were collected, Figures S7–S9.
3.4. Grafting of Molecules (PS, PEG and FA) on the MSN Surface
The different functionalized MSNs, varying PS, PEG and FA (Figure 1) and the linkage
approach, were synthesized and named as follows:
- RB-PEG-NP-a: RB (0.03 mmol), previously silylated with an equimolar ratio of APTMS
(0.03 mmol) in 20 mL of CH3CN under stirring for 1 h under inert atmosphere [109],
was directly coupled to the structural hydroxyl groups of MSN (40 mg) added af-
terward. The reaction was kept for 3 h and the nanoparticles were collected by
filtration. Then, RB-MSNs were re-suspended in 20 mL of CH3CN and then, NHS
ester-activated PEG (0.03 mmol), NHS-PEG (Figure 1), was added to react for 3 h
with the external primary amine group of NH-MSN to yield stable amide bonds and
releasing N-hydroxysuccinimide group (NHS). In this type of MSN, the pelygation
procedure of the external surface was carried out with three different PEG chains of
750, 2000, and 5000 Da. The corresponding samples were named RB-PEG750-NP-a,
RB-PEG2000-NP-a and RB-PEG5000-NP-a, respectively.
- RB-PEG-NP-b: RB was linked through its carboxylic group to the amine groups of
NH-MSN (40 mg) by the carbodiimide method. This method has been previously
described [105,109]. Briefly, NHS/EDC is added to RB in solution (0.03 mmol in 20 mL
of CH3CN) in equimolar concentration and stirring for 1 h in an inert atmosphere.
Then NH-MSN (40 mg) was directly added to the reaction mixture and kept stirring
for 3 h, and nanoparticles were collected. In a second step, PEG (0.03 mmol) with a
silylated group at one edge (Si-PEG, Figure 1) was externally anchored to the inherent
hydroxyl groups of RB-MSN (40 mg) by direct condensation reaction during 3 h.
- RB-PEG-NP-c: both RB (0.03 mmol), previously silylated according to the process
previously described in sample RB-PEG-NP-a, and Si-PEG (0.03 mmol) were simulta-
neously bound in CH3CN to the external hydroxyl groups of MSN (40 mg) following
the procedure previously mentioned.
- RB-NP-d: FA (0.03 mg) was added to RB-PEG-NP-c (40 mg), previously re-suspended
in CH3CN (20 mL), and was linked to the amine groups of RB-PEG-NP-c sample
through the carbodiimide method cited above.
For the rest of the PDT-nanosystems, denoted as PS-NP, with PS being the short
name of every PS (indicated in Figure 1), the linkage between PS and MSN is ruled out
by the main functional group at the PS (Figure 1). That is, the amine group of Th dye
is covalently linked to the carboxylic groups of COOH-MSN (previously treated with
NHS/EDC). Photosensitizers with silylated groups (BDP1, BDP3, BDP5 and BDP7) were
directly coupled to the hydroxyl groups of OH-MSN. Finally, PSs with carboxylic groups
(C6, BDP2, BDP4, and BDP6) were grafted to the external amine groups of nanoparticles
(NH-MSNs). Note here that C6 was linked by the previous carbodiimide methods but
BODIPYs (BDP2, BDP4, and BDP6) cannot withstand such conditions, and an alternative
synthetic route was employed. BODIPY-COOH was dissolved in CH3CN anhydride
(20 mL) at 0 ◦C, ethyl chloroformate and triethylamine were added dropwise in equimolar
concentration (0.03 mmol) and the system was kept under vigorously stirring for 30 min.
Then, NH-MSNs were added at rt and stirred for other 30 min. Finally, the functionalized
nanoparticles were washed with EtOH until a colorless supernatant was obtained.
In all these samples, Si-PEG (2000 Da) was tethered at the hydroxyl groups and FA
to the amine groups of MSNs. The exception was Th-MSN, in which FA was linked to
carboxyl groups by a previous chemical modification of FA, according to Scheme S2 and
Figures S10 and S11 [101]. Briefly, the terminal COOH group of FA was modified with
N-Boc-1,6-hexanediamine (Boc-HDA) and the amine group (FA-HDA) was obtained after
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removing the Boc group, according to [101]. The relative quantity of PS, PEG and FA added
to the reaction per mg of nanoparticles was equivalent for all PS-MSN samples.
3.5. Physicochemical and Photophysical Characterization
The size, shape and morphology of the silica nanoparticles were characterized by
electron microscopes, scanning electron microscopy (SEM) and transmission electron
microscopy (TEM). SEM images were obtained using a JEOL JSM-6400 (JEOL, Tokyo,
Japan) and TEM images were obtained using a Philips SuperTwin CM200 (Thermo Fisher
Scientific, Eindhoven, The Netherlands) at 200 kV. The nanoparticle size distribution was
analyzed by Image-J software (1.52u, National Institute of Health, Bethesda, MD, USA).
Dynamic light scattering (DLS) and Zeta potential (Zpot) measurements to analyze the
NP size and their stability in suspension were carried out using a Malvern Zetasizer Nano
ZS (Malvern Products, Madrid, Spain), which had a Helio-Neon laser (λ = 633 nm). FTIR
spectra were obtained from neat samples in powder using ATR technique in an Anity-1S
Shimadzu spectrometer (Izasa Scientific, Barcelona, Spain) (4000–400 cm−1 range) and
XPS spectra were recorded using a SPECS system (Berlin, Germany) with a Phoibos 150
1D-DLD analyzer and Al Kα (1486.7 eV) as monochromatic radiation.
The absorption spectra were recorded by UV-Vis-NIR Spectroscopy (model Cary 7000,
Agilent Technologies, Madrid, Spain) equipped with two lamps (halogen lamp for Vis-IR
region and deuterium lamp for UV region). In the case of the silica nanoparticle samples,
an integrating sphere (model Internal DRA 900, Livingston, UK) was used to reduce the
scatter of the samples. The fluorescence measurements were recorded with an Edinburgh
Instruments Spectrofluorimeter (FLSP920 model, Livingston, UK) equipped with a xenon
flash lamp 450 W as the excitation source. The fluorescence spectra were corrected from
the wavelength dependence on the detector sensibility.
The fluorescence quantum yields of the photosensitizers were measured by the relative
method, and different standard samples depending on the spectral region: coumarin 152
(Φfl = 0.19 in EtOH) for the blue region [128], PM597 (Φfl = 0.32 in cHex) [20] for the green
and cresyl violet (Φfl = 0.54 in CH3OH) [129] and zinc phthalocyanine (Φfl = 0.30 in 1%
pyridine in toluene) [130] for the red-visible region.
Radiative decay curves were recorded in the same Edinburgh Instrument by Time-
Correlated Single-Photon Counting Technique (TC-SPC), using a microchannel plate detec-
tor (Hamamatsu C4878) with picoseconds time resolution (≈20 ps). Fluorescence decay
curves were monitored at the maximum emission wavelength after excitation by means of
a fianium supercontinuous wavelength tunable laser with 150 ps FWHM pulses.
The singlet oxygen (1O2) production was determined by direct measurement of their
phosphorescence at 1276 nm employing NIR detector (InGaAs detector, Hamamatsu G8605-
23), integrated into the same Edinburgh spectrofluorimeter upon continuous monochro-
matic excitation (450 W Xenon lamp) of the sample. Singlet oxygen quantum yields (Φ∆PS)
were calculated by the relative method, using commercial photosensitizers as references:
Rose Bengal (RB, Φ∆PS = 0.86 in CH3OD), MeSBDP (CAS-1835282-63-7, Φ∆PS = 0.98 in
CH3OD and Φ∆PS = 0.91 in CHCl3) [131] and New Methylene Blue (NMB, Φ∆PS = 0.76
in CH3OD).
The amount of PSs in MSN was estimated photometrically, by reading the absorbance
value of a previously weighed amount of nanoparticles in a stable suspension and assuming
that the molar extinction coefficient of the dye was the same in solution as when grafted on
the nanoparticles.
3.6. In Vitro Assays
3.6.1. Cell Culture
Human cervical adenocarcinoma cells (HeLa cells, CCL2) purchased from ATCC were
grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% (v/v) fetal
bovine serum (FBS) and 50 U/mL penicillin and 50 mg/mL streptomycin, in a humidified
5% CO2 cells incubator at 37 ◦C. For the cytotoxicity study, cells were grown to monolayer
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confluency in 96-well microplates. For the internalization and subcellular localization
study, cells were seeded in glass-bottom 35 mm Petri dishes and subconfluent monolayers
were used.
3.6.2. Sample Preparation and In Vitro Exposures
PS-MSNs were suspended in PBS buffer (1·10−4 M) and stirred for at least 24 h before
the exposures. PSs alone were directly dissolved in DMSO (1·10−3 M). For the in vitro
exposures, cells were incubated for 24 h with 1, 5, 10, 50 and 100·10−7 M, final concentration
of each PS in solution or tethered at MSN nanosystem, in 10% FBS cell culture medium.
After 24 h exposure, cells were washed three times with serum-free culture medium and
maintained in the culture medium during irradiation (<30 min, depending on the fluence
rate of each light source) and post-treatment time (24 h).
Irradiations were performed using light-emitting diode (LED) devices: LED Par 64
Short Q4-18 (Showtec, Burgebrach, Holland) for blue (λab 455 nm) and green (λab 518 nm)
light and LED 36 W (KINGBO LED) for red (λab 655 nm), using a total light dosage (TLD)
between 10 and 15 Jcm−2, as it is shown in the Figure S12. The irradiation time, being in all
the cases shorter than 30 min, depends on the fluence rate of each LED according to the
following equation:
TLD (J/cm2) = fluence rate (mW/cm2) × treatment time (s)
Different LEDs were chosen depending on the main absorption band of each sample.
Parallel experiments were carried out by incubating the cells with each PS or PS-MSN
nanoplatforms without irradiation to test their toxicity in dark conditions. Unexposed cells
and cells exposed to 1% DMSO or MSN alone were used as controls. Four replicates of
each treatment were used, and experiments were repeated three times.
3.6.3. Confocal Microscopy
To evaluate internalization and subcellular localization of selected PS-MSN samples
through confocal microscopy, cells were incubated for 24 h with 1 µM of RB, RB-PEG-NP-d
or BDP6-NP in 10% FBS-supplemented DMEM culture medium. Unexposed cells were
used as control. After exposures, cells were washed three times with culture medium
and fixed with 0.4% paraformaldehyde for 10 min at 4 ◦C. Cells were then washed three
times with culture medium and observed under an Olympus Fluorview FV500 confocal
microscope (Hamburg, Germany). Fluorescence images were obtained under 561 nm
excitation and 565–616 nm emission range (Alexa 568) for RB samples and at 640 nm
excitation and 645–700 nm emission range for BDP-6 sample. Both fluorescence and
brightfield images were obtained at the same depth. Images were edited using Fiji software
(ImageJ 1.49a, National Institutes of Health, Bethesda, MD, USA).
3.6.4. Cell Viability (MTT) Assay
Dark and phototoxicity were assessed in HeLa cells using the thiazolyl blue tetra-
zolium bromide (MTT) assay following the manufacturer’s instructions. After exposures,
cells were incubated with a 50 µg/mL MTT solution for 3 h at 37 ◦C. Then, reduced for-
mazan product was extracted from cells with DMSO and the absorbance was measured at
570 nm in a Biotek EL 312 microplate spectrophotometer reader (Winooski, VT, USA). Cell
viability was expressed as the percentage with respect to control cells. Differences between
unexposed and treated cells were analyzed through the Kruskal-Wallis test followed by the
Dunn’s post hoc test. Differences between dark and light exposures at the same concentra-
tions were analyzed through Mann-Whitney U test. EC50 values were calculated using the
Probit test. All statistical analyses were performed using the SPSS 23.0 software (Chicago,
IL, USA). Significance level was globally established at 5% (p < 0.05).
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4. Conclusions
Photosensitized silica nanoparticles functionalized with PEG and FA proved to be
suitable and biocompatible nanosystems able to overcome some of the drawbacks of
PS, as follows: (i) avoidance of cytotoxicity under dark conditions, ensuring safe use in
clinical trials for cancer treatment; (ii) increased internalization, providing a better PDT
performance in HeLa cells in comparison with PSs free in solution. Overall, photosensitized
silica nanoparticles with BODIPY-based PSs showed higher phototoxicity compared to
commercial PSs (i.e., RB-NP vs. BDP3-NP or BDP5-NP under green light and C6-NP vs.
BDP6-NP under red light irradiation). Finally, BDP-PEG-FA-MSN systems under red light
irradiation also enabled fluorescence bioimaging, making them promising platforms to be
implemented in PDT.
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